Margetuximab Developer Seeks FDA Approval for the Treatment of Metastatic HER+ Breast…

A biologics license application has been submitted to the FDA for margetuximab in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer, according to a press release from MacroGenics, Inc.

Read the full article here

Related Articles